[HTML][HTML] Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)–related interstitial lung disease/pneumonitis—focus on proactive monitoring, diagnosis …
Abstract Trastuzumab deruxtecan (T-DXd; DS-8201) is an antibody-drug conjugate targeting
human epidermal growth factor receptor 2. Interstitial lung disease (ILD)/pneumonitis is an …
human epidermal growth factor receptor 2. Interstitial lung disease (ILD)/pneumonitis is an …
Interstitial lung disease associated with anti-HER2 anti-body drug conjugates: results from clinical trials and the WHO's pharmacovigilance database
Z Ma, Y Zhang, M Zhu, L Feng, Y Zhang… - Expert review of clinical …, 2022 - Taylor & Francis
Background Interstitial lung disease (ILD) events associated with anti-human epidermal
growth factor receptor 2 (HER2) antibody-drug conjugates (ADCs) have aroused wide …
growth factor receptor 2 (HER2) antibody-drug conjugates (ADCs) have aroused wide …
Toward Project Optimus for Oncology Precision Medicine: Multi‐Dimensional Dose Optimization Enabled by Quantitative Clinical Pharmacology.
K Venkatakrishnan… - Clinical Pharmacology & …, 2022 - search.ebscohost.com
Project Optimus is a major US Food and Drug Administration (FDA) initiative aimed at dose
optimization in oncology drug development, moving away from the maximum tolerated dose …
optimization in oncology drug development, moving away from the maximum tolerated dose …
NEDDylated Cullin 3 mediates the adaptive response to topoisomerase 1 inhibitors
DNA topoisomerase 1 (TOP1) inhibitors are mainstays of anticancer therapy. These drugs
trap TOP1 on DNA, stabilizing the TOP1-cleavage complex (TOP1-cc). The accumulation of …
trap TOP1 on DNA, stabilizing the TOP1-cleavage complex (TOP1-cc). The accumulation of …
Clinical Guidance on the monitoring and management of Trastuzumab Deruxtecan (T-DXd)-Related adverse events: insights from an Asia-Pacific Multidisciplinary …
JWY Chiu, SC Lee, JC Ho, YH Park, TC Chao, SB Kim… - Drug Safety, 2023 - Springer
Abstract Trastuzumab deruxtecan (T-DXd)—an antibody–drug conjugate targeting the
human epidermal growth factor receptor 2 (HER2)—improved outcomes of patients with …
human epidermal growth factor receptor 2 (HER2)—improved outcomes of patients with …
Realizing the promise of project optimus: challenges and emerging opportunities for dose optimization in oncology drug development
W Gao, J Liu, B Shtylla… - CPT …, 2024 - Wiley Online Library
Project Optimus is a US Food and Drug Administration Oncology Center of Excellence
initiative aimed at reforming the dose selection and optimization paradigm in oncology drug …
initiative aimed at reforming the dose selection and optimization paradigm in oncology drug …
Safety of trastuzumab deruxtecan: A meta‐analysis and pharmacovigilance study
Z Guo, Y Ding, M Wang, J Liu, Q Zhai… - Journal of Clinical …, 2022 - Wiley Online Library
Abstract What Is Known and Objective This study aimed to explore the safety profile of
trastuzumab deruxtecan (T‐DXd, formerly DS‐8201a) using multi‐source medical data …
trastuzumab deruxtecan (T‐DXd, formerly DS‐8201a) using multi‐source medical data …
[HTML][HTML] Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial …
D Wekking, M Porcu, B Pellegrino, E Lai, G Mura… - ESMO open, 2023 - Elsevier
Trastuzumab deruxtecan (T-DXd), a human epidermal growth factor receptor 2 (HER2)-
directed antibody-drug conjugate (ADC), has altered the treatment landscape in breast …
directed antibody-drug conjugate (ADC), has altered the treatment landscape in breast …
High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive/mutated malignancies: a …
P Ma, H Tian, Q Shi, R Liu, Y Zhang, X Qi… - Expert Opinion on Drug …, 2023 - Taylor & Francis
ABSTRACT Background T-DM1 and T-DXd are two promising antibody-drug conjugates for
treating advanced HER2-positive breast cancer and HER2-mutated lung cancer …
treating advanced HER2-positive breast cancer and HER2-mutated lung cancer …
[HTML][HTML] Current management and future perspectives in metastatic HER2-positive breast cancer
L Sánchez-Lorenzo, A Bachiller, C Gea… - Seminars in Oncology …, 2024 - Elsevier
Objective Metastatic HER2-positive breast cancer remains a significant clinical challenge
with a poor prognosis. The introduction of anti-HER2 therapies has significantly improved …
with a poor prognosis. The introduction of anti-HER2 therapies has significantly improved …